Citadel Advisors »

Tvardi Therapeutics shares owned by Citadel Advisors

Quarter-by-quarter ownership of Tvardi Therapeutics (TVRD) shares owned by Citadel Advisors from 13F filings

Historical chart of Citadel Advisors investment in Tvardi Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Tvardi Therapeutics held by Citadel Advisors consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Tvardi Therapeutics by Citadel Advisors

Quarter filed Position value Share count Share price at filing
2025-12-31 $93k 22k 4.30

More positions owned by Citadel Advisors

Spdr S&p 500 Etf Tr Tr Unit (SPY)
Invesco Qqq Tr Unit Ser 1 Call Option (QQQ)
Tesla Motors Call Option (TSLA)
NVIDIA Corporation Call Option (NVDA)
Apple Call Option (AAPL)
Meta Platforms Cl A Call Option (META)
Amazon Call Option (AMZN)
Spdr Gold Tr Gold Shs Call Option (GLD)
Alphabet Cap Stk Cl A Call Option (GOOGL)
Microsoft Corporation Call Option (MSFT)
Ishares Tr Russell 2000 Etf Call Option (IWM)
Broadcom Call Option (AVGO)
Netflix Call Option (NFLX)
Alphabet Cap Stk Cl C Call Option (GOOG)
Advanced Micro Devices Call Option (AMD)

View all positions for Citadel Advisors

Top funds holding Tvardi Therapeutics

Slate Path Capital
Vanguard Group
BlackRock
Vanguard Capital Management
American Financial Group
Geode Capital Management
State Street Corporation
Renaissance Technologies
Silvercrest Asset Management Group
Duncan Williams Asset Management
Squarepoint Ops
UBS Group
Northern Trust
Jane Street
Vanguard Fiduciary Trust

View all funds holding Tvardi Therapeutics